---
title: "Global X S&P 500 U.S. Mkt Ldr TOP 50 ETF | 8-K: FY2026 Q2 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295849526.md"
datetime: "2026-08-13T21:23:27.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295849526.md)
  - [en](https://longbridge.com/en/news/295849526.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295849526.md)
---

# Global X S&P 500 U.S. Mkt Ldr TOP 50 ETF | 8-K: FY2026 Q2 Revenue: USD 0

Revenue: As of FY2026 Q2, the actual value is USD 0.

EPS: As of FY2026 Q2, the actual value is USD -2.94.

EBIT: As of FY2026 Q2, the actual value is USD -4.12 M.

### Financial Performance (Three Months Ended June 30, 2026 vs. 2025)

#### Net Loss

Calidi Biotherapeutics, Inc. reported a net loss of - $4,160 thousand for the second quarter of 2026, compared to - $5,761 thousand for the same period in 2025. The net loss attributable to common stockholders was - $4.2 million for Q2 2026, versus - $5.7 million for Q2 2025.

#### Net Loss Per Share

Net loss per share was - $2.94 for the second quarter of 2026, compared to - $31.75 for the comparable period in 2025, after adjusting for a 1-for-16 reverse stock split completed in July 2026.

#### Operating Expenses

-   Research and Development Expenses were $2,558 thousand for Q2 2026, which was unchanged from $2,593 thousand in Q2 2025.
-   General and Administrative Expenses were $1,592 thousand for Q2 2026, a reduction of $1.5 million or 48% compared to $3,071 thousand in Q2 2025.

### Financial Position (as of June 30, 2026 vs. December 31, 2025)

#### Cash and Restricted Cash

Calidi Biotherapeutics, Inc. had $4,071 thousand in cash and $0.2 million in restricted cash as of June 30, 2026. This compares to $5,600 thousand in cash and $0.2 million in restricted cash as of December 31, 2025.

#### Total Assets

Total assets were $7,204 thousand as of June 30, 2026, down from $8,857 thousand as of December 31, 2025.

#### Total Liabilities

Total liabilities amounted to $4,071 thousand as of June 30, 2026, decreasing from $5,098 thousand as of December 31, 2025.

#### Total Equity

Total equity was $3,133 thousand as of June 30, 2026, compared to $3,759 thousand as of December 31, 2025.

### Business Developments and Operational Metrics

-   Calidi Biotherapeutics, Inc. received positive pre-IND feedback from the U.S. FDA for CLD-401, agreeing on the development strategy for a first-in-human study.
-   The company showcased the versatility of its RedTail platform at the 2026 ASCO Annual Meeting with new CLD-501 data and is advancing its EpCam-targeted in situ TCE program.
-   The Board of Directors was strengthened with the addition of Corsee Sanders, Ph.D.

### Outlook / Guidance

Calidi Biotherapeutics, Inc. anticipates its lead drug candidate, CLD-401, entering the clinic during the first quarter of 2027, with plans to dose the first patient in a phase 1 trial. The company intends to maintain a tight focus on expense management to ensure sufficient capital for advancing its pipeline.

### Related Stocks

- [FLAG.US](https://longbridge.com/en/quote/FLAG.US.md)

## Related News & Research

- [Is SLB’s (SLB) Large ESOP Shelf Filing Reframing Its Capital Allocation Priorities?](https://longbridge.com/en/news/295990206.md)
- [Applied Materials Stock Is Down on Earnings. Here’s What Barchart Options Data Says Could Come Next for AMAT.](https://longbridge.com/en/news/295967382.md)
- [4-Oil set for weekly gains after US threatens indefinite blockade of Iran](https://longbridge.com/en/news/295923118.md)
- [Exodus Movement, Inc. (NYSEAMERICAN:EXOD) Short Interest Update](https://longbridge.com/en/news/295981682.md)
- [Why Is Duolingo Stock Falling Friday?](https://longbridge.com/en/news/295959246.md)